Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients

Djebbari, Faouzi; Rampotas, Alexandros; Vallance, Grant; Panitsas, Fotios; Basker, Nanda; Sangha, Gina; Salhan, Beena; Karim, Farheen; Al-Kaisi, Firas; Gudger, Amy; Ngu, Loretta; Poynton, Matt; Lam, Ho Pui Jeff; Morgan, Lowri; Yang, Laura; Young, Jennifer; Walker, Mairi; Tsagkaraki, Ismini; Anderson, Laura; Chauhan, Saleena Rani; Maddams, Rebecca; Soutar, Richard; Triantafillou, Margarita; Prideaux, Steve; Obeidalla, Abubaker; Eyre, Toby A; Bygrave, Ceri; Kothari, Jaimal; Basu, Supratik; Ramasamy, Karthik

Abstract

No abstract available

Citation

Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Kothari J, Basu S, Ramasamy K. Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients. Br J Haematol. 2023 Apr;201(1):162-167. doi: 10.1111/bjh.18672. Epub 2023 Jan 31

Type

Article